HOME >> BIOLOGY >> NEWS
ChemGenex uses genomics approach to develop new anticancer drug, predict possible side effects

Gene expression changes in response to drugs in cell culture and living systems provide unique insights for their development and use

MENLO PARK, CA (October 30, 2001): Most genomics research is currently aimed at identifying and validating new gene targets for use in early stage drug discovery. However, genomics can also play a key role now in preclinical and clinical drug development, including predicting potential drug toxicities and helping developers design clinical trials, say scientists from ChemGenex Therapeutics. They discussed data today illustrating the use of chemical genomics approaches in evaluating the potential of their investigational drug called Ceflatonin against leukemias and human solid tumors. The researchers presented their findings at the American Association of Cancer Research National Cancer Institute European Organization for Research and Treatment of Cancer conference on Molecular Targets and Cancer Therapeutics taking place from October 29 to November 3 in Orlando, Florida.

Understanding how genes perform in response to chemicals in cell cultures, as well as in diseased and normal tissues in living systems can help researchers identify and evaluate potential new drugs more efficiently than ever before, said Dennis Brown, Ph.D., chairman, chief executive officer and founder of ChemGenex Therapeutics, Inc.

Such knowledge can help spotlight possible drug toxicities, as well as identify which patients may best benefit from treatment with a specific drug, he continued. In addition, chemical genomics can aid in the design of efficient clinical trials by helping trial designers predict the most effective doses and dose scheduling, as well as provide key insights into drug bioavailability, distribution and metabolism. Using genomics in this way to help patients receive most effectively those medicines that will be most useful to them is a major goal of the genomics revolution.

Based on its chem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
30-Oct-2001


Page: 1 2 3

Related biology news :

1. International symposium on nutritional genomics
2. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics
3. Full promise of genomics in disease research yet to be realized
4. Pharmacogenomics could replace trial-and-error with science from the human genome
5. Dartmouth Medical School awarded $9 million grant for genomics research
6. Functional genomics enables easy target identification and drives drug discovery
7. Library on a Slide: Whole genome microarrays for comparative genomics
8. New genomics tool boosts diabetes research
9. Bacteriophage genomics approach to antimicrobial drug discovery published in Nature Biotechnology
10. Emerging frontiers genomics grant for blue-green bacteria
11. What can the genomics revolution teach us about global change?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... Jan. 18, 2017  In vitro diagnostic (IVD) companies ... and acquisitions (M&A), and Kalorama Information expects that trend ... have been shifting. Generally, uncertainty in reimbursement and healthcare ... U.S. has changed the acquisitions landscape. Instead of looking ... companies buying partners outside of their home country and ...
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
(Date:1/12/2017)...  New research undertaken by Fit Small Business ... participants were simply asked which office technology had they not ... standard issue.  Insights on what will be key ... futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... , February 17, 2017 ... Market by Product (Consumables, Service), Type (Safety, Efficacy, ... Development, Drug Discovery and Development, Disease-Risk) - Global ... is projected to reach USD 53.34 Billion by ... at a CAGR of 13.8% during the forecast ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched work to ... industry. Pilot studies are about to get under way for the framework, which is ... innovations. The concept is expected to be transferred eventually to other industries that also ...
(Date:2/16/2017)... 16, 2017  ArmaGen, Inc., a privately held ... treat severe neurological disorders, today reported preliminary evidence ... the company,s investigational therapy for the treatment of ... type I, or MPS I). The initial results ... presented today at the 13 th annual ...
(Date:2/16/2017)... 16, 2017 UCHealth ( Aurora, Colorado ... for pulmonary nodule patient management. In addition to optimizing ... spot on the lung, UCHealth looks to improve provider ... entry. Stephanie Brown, RN , Thoracic ... patients with an Excel spreadsheet, which was extremely arduous ...
Breaking Biology Technology:
Cached News: